Titan Pharmaceuticals Inc. buy melinda
Start price
25.08.17
/
50%
€276.01
Target price
27.12.17
€568.26
Performance (%)
-20.59%
End price
27.12.17
€219.19
Summary
This prediction ended on 27.12.17 with a price of €219.19. The prediction for Titan Pharmaceuticals Inc. disappointed with a performance of -20.59%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Titan Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -2.385% | 3.986% | 16.836% | 16.377% |
| iShares Nasdaq 100 | -4.527% | -0.258% | 18.824% | 29.987% |
| iShares Nikkei 225® | -4.129% | 4.382% | 10.912% | -1.507% |
| iShares S&P 500 | -2.885% | 1.387% | 20.391% | 35.258% |
Comments by melinda for this prediction
In the thread Titan Pharmaceuticals Inc diskutieren
pharma
SOUTH SAN FRANCISCO, Kalifornien. , 24. August 2017 / PRNewswire /: (NASDAQ Anwendung) hat heute bekannt gegeben , dass die Food and Drug Administration (FDA) die New Drug (IND) für seine Ropinirol Implantate zur Behandlung von Anzeichen und Symptomen der Parkinson-Krankheit zugelassen hat. Die Phase 1/2 der klinischen Studie bei Patienten in Kürze beginnen.
(Vom Mitglied beendet)
Stopped prediction by melinda for Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€4.17
24.10.20
24.10.20
€9.00
04.11.21
04.11.21
-65.11%
05.11.21
05.11.21
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€39.68
05.10.18
05.10.18
€81.18
22.10.18
22.10.18
44.72%
22.10.18
22.10.18
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€172.10
23.02.18
23.02.18
€194.83
22.03.18
22.03.18
22.58%
22.03.18
22.03.18
Titan Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€891.36
08.07.16
08.07.16
€1,298.9
09.01.17
09.01.17
-18.94%
09.01.17
09.01.17